Altimmune (ALT) Common Equity (2010 - 2026)
Altimmune (ALT) posted quarterly Common Equity of $284.0 million for Q1 2026, up 99.76% year-over-year from $142.2 million in Q1 2025, and up 26.28% quarter-over-quarter from $224.9 million in Q4 2025.
Altimmune (ALT) Common Equity (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Common Equity for 17 consecutive years, with $284.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 99.76% year-over-year to $284.0 million; the TTM figure through Mar 2026 stood at $284.0 million (up 99.76% YoY), while the FY2025 annual figure was $224.9 million, up 82.09% from the prior year.
- Common Equity grew to $284.0 million in Q1 2026 per ALT's latest filing, from $224.9 million in the prior quarter.
- Across five years, Common Equity topped out at $284.0 million in Q1 2026 and bottomed at $123.5 million in Q4 2024.
- Historically, Common Equity has averaged $178.2 million across 5 years, with a median of $172.9 million in 2024.
- Annual changes were most pronounced in 2024 — Common Equity plunged 36.37% — and 2026, when it surged 99.76%.
- Altimmune's Common Equity stood at $185.3 million in 2022, then increased by 4.75% to $194.1 million in 2023, then slumped by 36.37% to $123.5 million in 2024, then soared by 82.09% to $224.9 million in 2025, then gained by 26.28% to $284.0 million in 2026.
- Business Quant data shows ALT's Common Equity at $284.0 million in Q1 2026, $224.9 million in Q4 2025, and $185.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | 474.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 474.21 Mn |
| Mar 31, 2026 | 283.99 Mn |
| Dec 31, 2025 | 224.89 Mn |
| Sep 30, 2025 | 185.60 Mn |
| Jun 30, 2025 | 161.37 Mn |
| Mar 31, 2025 | 142.16 Mn |
| Dec 31, 2024 | 123.51 Mn |
| Sep 30, 2024 | 133.38 Mn |
| Jun 30, 2024 | 152.53 Mn |
| Mar 31, 2024 | 172.94 Mn |
| Dec 31, 2023 | 194.10 Mn |
| Sep 30, 2023 | 150.40 Mn |
| Jun 30, 2023 | 167.71 Mn |
| Mar 31, 2023 | 167.73 Mn |
| Dec 31, 2022 | 185.29 Mn |
| Sep 30, 2022 | 205.03 Mn |
| Jun 30, 2022 | 194.54 Mn |
| Mar 31, 2022 | 184.87 Mn |
| Dec 31, 2021 | 199.14 Mn |
| Sep 30, 2021 | 209.26 Mn |